Total Funding
1
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
683713
Conatus Pharmaceuticals is focused on the development of human therapeutics to treat liver failures and cancer.
Acquired by 
Histogen
Steven J. Mento: Co-Founders, President and Chief Executive Officer, Board of DirectorsPast Role: Chiron Corporation, Vice President
Charles J. Cashion: Senior Vice President, Finance, Chief Financial Officer, and Secretary , Co-FoundersPast Role: Idun Pharmaceuticals, Chief Financial Officer
About the Company
Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to
date its development has been the primary focus of the Company.
Women Founded
